Clinical trials: HSV
Herpes Genitalis, Herpes Zoster
Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food
The objective of this study is to evaluate the safety and tolerability of single rising doses of ASP2151 under fasted condition in healthy male subjects.
- Trial name
- NCT02852876
- Testing
- ASP2151
- Where
- France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe Ltd.
Herpes
Hsv 1 and 2 Gowey Protocol Versus Placebo
This study will compare efficacy of versabase gel with 20% sarracenia purpurea versus placebo applied every 3-4 hours to herpes lesions.
- Trial name
- NCT01477879
- Testing
- Versabase gel with sarracenia purpurea 20% liquid extract
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Naturopaths International
Varicella Zoster Virus Infection, Herpes Simplex Virus Infection
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
A new paediatric formulation (oral liquid) has been developed for flexible and accurate dosing of valacyclovir in children. To establish the bioavailability of this new formulation, healthy volunteers will be exposed to the new…
- Trial name
- VALID-I (NCT01689285)
- Testing
- valacyclovir tablet, valacyclovir oral solution
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Herpes Simplex, Schizophrenia
Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia
The effects of Valacyclovir (VAV) augmentation or placebo (PLA) as adjuncts to conventional antipsychotic drug treatment will be evaluated among patients with schizophrenia who have been exposed to herpes simplex virus type 1…
- Conditions
- Herpes Simplex, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT01794897
- Testing
- Experimental: Valacyclovir treatment
- Where
- India
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Herpes Simplex Infections, Human Papillomavirus
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
- Conditions
- Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection
- Trial name
- NCT02715752
- Testing
- Gene-Eden-VIR/Novirin
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Center for the Biology of Chronic Disease
Herpes Zoster
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse administer the vaccine in…
- Trial name
- NCT01483378
- Testing
- Choosing to receive the vaccine
- Where
- 2 sites in United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Herpes Zoster
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to…
- Trial name
- NCT01954251
- Testing
- Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older
The purpose of this study is to assess immunogenicity and safety of GSK Biologicals' HZ vaccine when its first dose is co-administered with a pneumococcal polysaccharide conjugate vaccine (Prevenar13) in adults aged ≥50 YOA, as…
- Trial name
- NCT03439657
- Testing
- HZ/su vaccine GSK1437173A, Prevenar13
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 913 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Shingles, Herpes Zoster Infection
A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults
The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune system's reaction) of the study vaccine called Varicella Zoster Virus modRNA (VZV…
- Conditions
- Shingles, Herpes Zoster Infection, Human
- Trial name
- NCT05703607
- Testing
- Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection
- Where
- 35 sites in United States
- Volunteers
- 484 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections, Chlamydia Trachomatis
Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide
The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months.
- Conditions
- HIV Infections, Chlamydia Trachomatis, Neisseria Gonorrhoeae, Trichomonas Vaginitis
- Trial name
- NCT00213031
- Testing
- Carraguard (PC-515)
- Where
- Thailand
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Population Council
Herpes Zoster
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
- Trial name
- NCT06654700
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Labialis
Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis
A randomized study comparing the combination of valacyclovir and temovate gel (clobetasol gel) versus placebo for the treatment of recurrent herpes labialis (cold sores).
- Trial name
- NCT00297011
- Testing
- valacyclovir+clobetasol gel
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Utah
Herpes Zoster
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine
The purposes of the study are to evaluate the Safety, Tolerability, and Immunogenicity of different dose levels of recombinant herpes zoster vaccine with 2 doses 60 days apart in healthy subjects aged 40 years and older.
- Trial name
- NCT06801509
- Testing
- Recombinant Herpes Zoster Vaccine (SCTV04C) Low-Dose, Recombinant Herpes Zoster Vaccine (SCTV04C) High-Dose, Shingrix®
- Where
- China
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Herpes Zoster, Shingles
Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)
This study will determine whether ZOSTAVAX™ made with an alternative manufacturing process [ZOSTAVAX™ (AMP)] is well tolerated and immunogenic, and has a comparable immune response to ZOSTAVAX™.
- Trial name
- NCT01505647
- Testing
- Zoster Vaccine, Live (AMP), Zoster Vaccine, Live
- Volunteers
- 498 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)
The purpose of this study is to determine whether the investigational zoster vaccine, is generally well tolerated when administered to participants with a history of herpes zoster.
- Trial name
- NCT00322231
- Testing
- zoster vaccine live (ZOSTAVAX™)
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Lung Diseases, Herpesvirus Infections
Herpesvirus in Idiopathic Pulmonary Fibrosis
The purpose of this study is to: 1) to develop a method to quantify Epstein Barr Virus (EBV) load in lung tissue of humans and to determine whether EBV viral load is significantly higher in lung tissue from patients with…
- Trial name
- NCT00228670
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Emory University
Herpse Zoster
A Study on the Live-Attenuated Herpes Zoster Vaccine for Sequential Booster Immunization Following Recombinant Herpes Zoster Vaccine
Evaluate the immunogenicity after boost vaccination with the live attenuated herpes zoster vaccine.
- Trial name
- NCT07753265
- Testing
- live-attenuated zoster vaccine
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Postherpetic Neuralgia
New Topical Treatment for Continued Pain After Shingles
Shingles is an outbreak of rash or blisters on the skin that is caused by the same virus that causes chicken pox. Some people experience continued pain even after the shingles rash and blisters have healed; this pain is known as…
- Trial name
- NCT00566904
- Testing
- Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Biomedical Development Corporation
Epstein-Barr Virus Infection
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants
The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.
- Trial name
- NCT05831111
- Testing
- mRNA-1195.1, mRNA-1195.2, mRNA-1189
- Where
- 34 sites in United States
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
GATA2 Deficiency
Natural History Study of GATA2 Deficiency and Related Disorders
Background: GATA2 deficiency is a genetic disorder that can cause problems with a person s immune system and other body systems. Some people who have this disorder develop few problems from it.
- Trial name
- NCT01905826
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)